Caribou Biosciences Inc
NASDAQ:CRBU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (1.2), the stock would be worth $0.45 (79% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.6 | $2.13 |
0%
|
| 3-Year Average | 1.2 | $0.45 |
-79%
|
| 5-Year Average | 4.6 | $1.76 |
-18%
|
| Industry Average | 6.2 | $2.36 |
+11%
|
| Country Average | 3 | $1.16 |
-46%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
$45.2m
|
/ |
Jan 2026
$11.2m
|
= |
|
|
$45.2m
|
/ |
Dec 2026
$11.3m
|
= |
|
|
$45.2m
|
/ |
Dec 2027
$12.6m
|
= |
|
|
$45.2m
|
/ |
Dec 2028
$27.9m
|
= |
|
|
$45.2m
|
/ |
Dec 2029
$90.8m
|
= |
|
|
$45.2m
|
/ |
Dec 2030
$206.6m
|
= |
|
|
$45.2m
|
/ |
Dec 2031
$3B
|
= |
|
|
$45.2m
|
/ |
Dec 2032
$6.5B
|
= |
|
|
$45.2m
|
/ |
Dec 2033
$10.4B
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Caribou Biosciences Inc
NASDAQ:CRBU
|
202.7m USD | 5.6 | -1.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
348.9B USD | 6.6 | 83.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.4B USD | 6.1 | 23.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 5.8 | 18.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 8.4 | 27.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 4 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 10.7 | 37.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 3.5 | 31.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 3 |
| 70th Percentile | 5.3 |
| Max | 4 613 320.1 |
Other Multiples
Caribou Biosciences Inc
Glance View
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 97 full-time employees. The company went IPO on 2021-07-23. The firm is developing transformative clustered regularly interspaced short palindromic repeats (CRISPR) therapies for patients with devastating diseases. The Company’s CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), enables superior genome-editing precision to develop cell therapies that are specifically engineered for enhanced persistence. The company is advancing a pipeline of allogeneic, or off-the-shelf, chimeric antigen receptor (CAR)-T (CAR-T) and CAR-natural killer (CAR-NK) cell therapies for the treatment of patients with hematologic malignancies and solid tumors. Its lead product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 CAR-T cell therapy with programmed cell death protein 1 (PD-1) removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. The Company’s product candidate also includes CB-011, CB-012 and CB-012.
